back to top
- A Pill Instead of a Needle for Cancer-Associated Venous Thromboembolism? YES!January 10, 2018 | January-February 2018, Volume 15, Issue 1
Dr. Linkins considers oral direct anticoagulants as an attractive alternative to low-molecular-weight heparin injections to treat patients with cancer-associated VTE.
- What Is Old Is New Again in the Treatment of Severe Refractory Heparin-Induced ThrombocytopeniaOctober 10, 2017 | November-December 2017, Volume 14, Issue 6
Dr. Linkins reviews the use of IVIg for off-label treatment of severe heparin-induced thrombocytopenia that has proven refractory to standard measures.
- Tranexamic Acid: Another Tool for Treatment of Postpartum HemorrhageAugust 14, 2017 | September-October 2017, Volume 14, Issue 5
Dr. Linkins reviews the WOMAN study, which demonstrates the usefulness of tranexamic acid to reduce maternal mortality due to postpartum hemorrhage.
- More Than an Aspirin a Day to Keep Recurrent Venous Thromboembolism AwayJuly 01, 2017 | July-August 2017, Volume 14, Issue 4
Dr. Linkins compares reducing the intensity of anticoagulant therapy or switching to aspirin as options for patients who wish to continue being protected from the risk of VTE.
- Can Apixaban Succeed Where Others Have Failed?May 01, 2017 | May-June 2017, Volume 14, Issue 3
Dr. Linkins covers a study that compares apixaban with no anticoagulants for prevention of a composite of fatal and nonfatal venous thromboembolism in children with a central venous catheter and newly diagnosed ALL, lymphoma or mixed-phenotype acute leukemia.
- Antepartum LMWH is Not the Answer for Most Pregnant Women With a History of Placenta-Mediated ComplicationsMarch 01, 2017 | March-April 2017, Volume 14, Issue 2
Dr. Linkins discusses a study that supports moving away from conducting thrombophilic work-ups in pregnant women who experience placenta-mediated complications.
Dr. Linkins is associate professor in the Division of Hematology and Thromboembolism of the Department of Medicine at McMaster University. Her research interests include bleeding on anticoagulant therapy, cancer-associated thrombosis and diagnosis and treatment of heparin-induced thrombocytopenia.